8.39

2.63% 0.215

After Hours: 8.39

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $8.39, with a volume of 638.25K. It is up +2.63% in the last 24 hours and down -15.85% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$8.175

Open:

$8.18

24h Volume:

638.25K

Relative Volume:

0.88

Market Cap:

$436.02M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-2.5579

EPS:

-3.28

Net Cash Flow:

$-78.56M

1W Performance:

+2.32%

1M Performance:

-15.85%

6M Performance:

-68.20%

1Y Performance:

-27.67%

1-Day Range:

$8.03

$8.44

1-Week Range:

$7.975

$8.44

52-Week Range:

$7.90

$36.25

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (671)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

201

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

FDMT's Discussions on Twitter

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

02:11 AM

Vanguard Group Inc's Strategic Acquisition of Shares in 4D Molec - GuruFocus.com

02:11 AM

Oct 30, 2024

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Yahoo Finance

Oct 30, 2024

Oct 29, 2024

Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR

Oct 29, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 13.2% in October - MarketBeat

Oct 29, 2024

Oct 27, 2024

Assenagon Asset Management S.A. Has $16.68 Million Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat

Oct 27, 2024

Oct 25, 2024

Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations - StockTitan

Oct 25, 2024

Oct 23, 2024

nVerses Capital LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Oct 23, 2024

Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts

Oct 22, 2024

Oct 18, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 By Investing.com - Investing.com Australia

Oct 18, 2024

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 18, 2024

Oct 17, 2024

4D Molecular Therapeutics stock hits 52-week low at $8.52 - Investing.com India

Oct 17, 2024

Oct 16, 2024

Gene therapy for managing neovascular macular degeneration - Ophthalmology Times Europe

Oct 16, 2024

Oct 14, 2024

Recent Insider Activity Suggests Potential Gains for 4D Molecular Therapeutics Inc (FDMT) - Knox Daily

Oct 14, 2024